ARTIS Ventures

Astra makes history as it will be become the first publicly traded space company on Nasdaq upon completion of its merger with Holicity, a special purpose acquisition company (SPAC), valued at $2.1B! This transaction takes us a step closer to our mission of improving life on Earth from space by fully funding our plan to provide daily access to low Earth orbit from anywhere on the planet, said Chris Kemp, Founder, Chairman and CEO of Astra. Congratulations to the entire team on all the hard work to get to today's historic milestone and becoming the fastest privately-funded company in history to demonstrate orbital launch capability!!

With #metagenomics, it could be possible to detect potentially life-threatening infections through one test, at one time, allowing for improved disease management read more from IDbyDNA CEO Dr. Guochun Liao in Forbes. Read more from him at:

Now more than ever, the world and particularly, the Department of Defense (DoD) is in need of innovative solutions that can better identify pathogens and mitigate the spread of disease and other health threats, said Dr. Guochun Liao, founder and CEO of IDbyDNA. This program will integrate our innovative technology in an effort to leapfrog current approaches to pathogen detection and better support biosurveillance labs globally. IDbyDNA will continue to seek out opportunities to partner with the public sector to leverage clinical metagenomics for the advancement of better diagnostic solutions.

The Moderna and Pfizer/BioNTech SE #covidvaccines are both based on similar mRNA vaccine technology, but the newly authorized AstraZeneca / University of Oxford vaccine uses an adenovirus vector. How do they compare? What are the key differences? We've compiled a chart below :

Congrats to Jennifer Doudna, PhD, for being awarded the Nobel prize related to her transformative breakthroughs in CRISPR science. Important advancements such as hers are now being applied to find cures for major diseases by companies such as Excision BioTherapeutics.

Congrats to Versa Networks for being named a Leader in Gartner's 2020 WAN Edge Magic Quadrant report! Versa is listed in the top three #sdwan vendors out of 80 in the entire industry. Focus, determination and hard work pays. https://www.businesswire.com//Versa-Networks-Has-Been-Reco

We're proud to back the Climax Foods team as they work toward their mission of making the future of food more sustainable while still optimizing for nutrition, texture, cost and flavor. Welcome to the team!

Welcome to the ARTIS team, Lemonaid Health! We are proud to announce our most recent partnership with Paul Johnson and the Lemonaid Team. We were impressed by the team's growth to date and look forward to watching the team continue to improve access to patient care online through virtual primary care and pharmacy solutions. #telemedicine #virtualcare #onlinepharmacy #patientaccess #primarycare #vcfunding

Our #Covid19 healthcare innovation tracker has resumed our weekly updates. Check out the latest here in addition to our new website! www.av.co/covid #fightthepandemic

Welcome to the family, Activ Surgical! We are proud to partner with the Activ Surgical team to support their mission of advancing autonomous and collaborative surgery through the integration of computer vision, artificial intelligence and robotics. We are also excited to announce that ARTIS Principal Ameena El-Bibany will be joining the board.

Congrats to Versa Networks - recognized as the 2020 Communications Solutions Product of the Year Award. Well deserved!

We're proud to have led Second Front Systems's $6 Million seed round with Kleiner Perkins and others, to provide immediate impact to national security by embracing AI, biotech, and cyber tech.

Versa Networks named leading secure SD-WAN vendor by Dell'Oro Group https://channelvisionmag.com/delloro-group-names-versa-the/

A great deep dive on Locus Biosciences by Clinical Leader. We turn the bacterial immune system back on itself, using the Cas3 mechanism to recognize and destroy the bacterial cell’s DNA, says Joseph Nixon, SVP of business development at Locus Biosciences. We use bacteriophage that have been engineered to deliver the CRISPR-Cas3 constructs into the target bacteria, which we call crPhage.

It’s always, the devil’s in the details, said ARTIS Partner Vasudev Bailey as he discusses lessons learned from innovation in new healthcare technologies like Proteus with Elise Reuter. Read more here:

Register here: https://www.illumina.com///2020/sars-cov-2-detection-.html Join us now as IDbyDNA and partner Illumina co-host a webinar to provide clinical metagenomic insights on detection of respiratory pathogens, including #SARSCov2, using #NGS and analysis with IDbyDNA's #Explify Platform.